Detailed information for compound 227299

Basic information

Technical information
  • TDR Targets ID: 227299
  • Name: N-(4-amidinobenzyl)-2-[5-chloro-3-[isopropyl( methyl)amino]-2-keto-6-phenyl-pyrazin-1-yl]ac etamide
  • MW: 466.963 | Formula: C24H27ClN6O2
  • H donors: 2 H acceptors: 2 LogP: 2.55 Rotable bonds: 9
    Rule of 5 violations (Lipinski): 1
  • SMILES: O=C(Cn1c(c2ccccc2)c(Cl)nc(c1=O)N(C(C)C)C)NCc1ccc(cc1)C(=N)N
  • InChi: 1S/C24H27ClN6O2/c1-15(2)30(3)23-24(33)31(20(21(25)29-23)17-7-5-4-6-8-17)14-19(32)28-13-16-9-11-18(12-10-16)22(26)27/h4-12,15H,13-14H2,1-3H3,(H3,26,27)(H,28,32)
  • InChiKey: QQECRYRPSMHCPW-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

  • N-(4-amidinobenzyl)-2-[5-chloro-3-(isopropyl-methyl-amino)-2-keto-6-phenyl-pyrazin-1-yl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-[methyl(propan-2-yl)amino]-2-oxo-6-phenylpyrazin-1-yl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-[isopropyl(methyl)amino]-2-oxo-6-phenyl-pyrazin-1-yl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-[isopropyl(methyl)amino]-2-oxo-6-phenyl-1-pyrazinyl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-[methyl(propan-2-yl)amino]-2-oxo-6-phenyl-pyrazin-1-yl]ethanamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-(methyl-propan-2-ylamino)-2-oxo-6-phenylpyrazin-1-yl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-(isopropyl-methyl-amino)-2-oxo-6-phenyl-pyrazin-1-yl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-(isopropyl-methylamino)-2-oxo-6-phenyl-1-pyrazinyl]acetamide
  • N-[(4-carbamimidoylphenyl)methyl]-2-[5-chloro-3-(methyl-propan-2-yl-amino)-2-oxo-6-phenyl-pyrazin-1-yl]ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens coagulation factor II (thrombin) Starlite/ChEMBL References
Homo sapiens coagulation factor III (thromboplastin, tissue factor) References
Homo sapiens Coagulation factor VII/tissue factor Starlite/ChEMBL References
Homo sapiens coagulation factor VII (serum prothrombin conversion accelerator) References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Echinococcus granulosus glycoprotein Antigen 5 coagulation factor VII (serum prothrombin conversion accelerator) 466 aa 384 aa 23.7 %

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Schistosoma mansoni adenosine deaminase 0.1826 1 1
Onchocerca volvulus 0.0748 0.3553 0.3553
Trypanosoma cruzi AMP deaminase, putative 0.1158 0.6004 1
Trypanosoma brucei AMP deaminase, putative 0.1158 0.6004 0.5
Leishmania major adenine aminohydrolase 0.1826 1 1
Entamoeba histolytica adenosine deaminase, putative 0.1826 1 1
Loa Loa (eye worm) hypothetical protein 0.1078 0.5527 0.4718
Trypanosoma cruzi AMP deaminase, putative 0.1158 0.6004 1
Trypanosoma brucei AMP deaminase, putative 0.1158 0.6004 0.5
Trypanosoma cruzi AMP deaminase, putative 0.1158 0.6004 1
Trypanosoma brucei adenosine monophosphate deaminase, putative 0.1158 0.6004 0.5
Leishmania major AMP deaminase, putative,amp deaminase-like protein 0.1158 0.6004 0.3803
Loa Loa (eye worm) hypothetical protein 0.1078 0.5527 0.4718
Loa Loa (eye worm) AMP deaminase 0.1158 0.6004 0.5282
Loa Loa (eye worm) hypothetical protein 0.0748 0.3553 0.2387
Onchocerca volvulus Adenosine deaminase homolog 0.1826 1 1
Trypanosoma cruzi AMP deaminase, putative 0.1158 0.6004 1
Schistosoma mansoni adenosine deaminase-related 0.1826 1 1
Plasmodium falciparum adenosine deaminase 0.1826 1 1
Loa Loa (eye worm) hypothetical protein 0.1078 0.5527 0.4718
Mycobacterium ulcerans adenosine deaminase 0.1826 1 0.5
Plasmodium vivax adenosine deaminase, putative 0.1826 1 1
Treponema pallidum adenosine deaminase 0.1826 1 0.5
Loa Loa (eye worm) hypothetical protein 0.1078 0.5527 0.4718
Leishmania major AMP deaminase, putative,adenosine monophosphate deaminase-like protein 0.1158 0.6004 0.3803
Leishmania major adenosine monophosphate deaminase, putative,AMP deaminase, putative 0.1158 0.6004 0.3803
Toxoplasma gondii Adenosine/AMP deaminase domain-containing protein 0.1826 1 1
Onchocerca volvulus AMP deaminase 2 homolog 0.1158 0.6004 0.6004
Leishmania major AMP deaminase, putative 0.1158 0.6004 0.3803
Trichomonas vaginalis adenosine deaminase, putative 0.1826 1 0.5
Trypanosoma brucei AMP deaminase, putative 0.1158 0.6004 0.5
Entamoeba histolytica adenosine deaminase, putative 0.1826 1 1
Mycobacterium tuberculosis Probable adenosine deaminase Add (adenosine aminohydrolase) 0.1826 1 0.5
Echinococcus granulosus adenosine deaminase 0.1826 1 1
Trichomonas vaginalis adenosine deaminase, putative 0.1826 1 0.5
Mycobacterium leprae Probable adenosine deaminase Add (ADENOSINE AMINOHYDROLASE) 0.1826 1 0.5
Trypanosoma cruzi AMP deaminase, putative 0.1158 0.6004 1
Toxoplasma gondii Adenosine/AMP deaminase domain-containing protein 0.1826 1 1
Trypanosoma cruzi adenosine monophosphate deaminase-like protein, putative 0.1158 0.6004 1
Echinococcus multilocularis adenosine deaminase 0.1826 1 1
Loa Loa (eye worm) hypothetical protein 0.1826 1 1
Trypanosoma cruzi adenosine monophosphate deaminase, putative 0.1158 0.6004 1

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 9.1 uM Inhibitory activity against tissue coagulation factor VII complex was determined (TF/VIIa complex) ChEMBL. 12954058
IC50 (binding) = 9.1 uM Inhibitory activity against tissue coagulation factor VII complex was determined (TF/VIIa complex) ChEMBL. 12954058
IC50 (binding) = 19.9 uM Inhibitory activity against thrombin (IIa) was determined ChEMBL. 12954058
IC50 (binding) = 19.9 uM Inhibitory activity against thrombin (IIa) was determined ChEMBL. 12954058

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.